Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.57 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 7/20 | 0.85 |
| ▸ | HTR2A | P28223 | 4/20 | 0.85 |
| ▸ | HTR2B | P41595 | 3/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | HTR5A | P47898 | 10/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL221132 | 1.00 | HTR1A (0.85) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL1848914 | 1.00 | HTR1A (0.85) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL1774275 | 0.93 | HTR1A (0.90) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL1957 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL29396422 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL3273179 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL2761861 | 0.91 | HTR1A (0.86) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| SCHEMBL1437 | 0.91 | HTR1A (0.98) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL2166 | 0.91 | HTR1A (0.98) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL5042399 | 0.90 | HTR1A (0.96) | HTR1AHTR2AHTR2BADRA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115477611-B | MRGPRX2 antagonists for the treatment of pseudoallergy | 香港大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-115477611-A | MRGPRX2 antagonists for the treatment of pseudoallergy | 香港大学 | 2022-12-16 | — | — | CN | disclosed |
| US-9889126-B2 | Use of naratriptan in the treatment of rosacea | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20170027922-A1 | USE OF NARATRIPTAN IN THE TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-02 | — | — | US | disclosed |
| EP-2774605-A1 | Pharmaceutical composition comprising almotriptan malate having uniform drug distribution and potency | Galenicum Health S.L. (ES) | 2014-09-10 | — | — | EP | disclosed |
| US-8734830-B2 | Manufacturing method and apparatus of ultrafine particles having uniform particle size distribution | KOREA UNITED PHARM. INC. (KR) | 2014-05-27 | — | — | US | disclosed |
| WO-2011124570-A2 | ORAL FILM FORMULATION | LABTEC GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| EP-2374448-A1 | Oral film formulation | Labtec GmbH (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20110240504-A1 | METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS | APOTEX TECHNOLOGIES INC. (CA) | 2011-10-06 | — | — | US | disclosed |
| EP-2370043-A1 | METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS | Apotex Technologies Inc. (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-20110200678-A1 | MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION | THE INDUSTRY METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTIO (KR) | 2011-08-18 | — | — | US | disclosed |
| WO-2010063114-A1 | METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS | APOTEX TECHNOLOGIES INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| EP-2172199-A1 | Sustained release tablet comprising pramipexole | Pharmacia Corporation (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090143387-A1 | SUSTAINED-RELEASE TABLET COMPOSITION | PFIZER INC | 2009-06-04 | — | — | US | disclosed |
| US-20070196481-A1 | Sustained-release tablet composition | PHARMACIA CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196481-A1 | Sustained-release tablet composition | SI, ABCB11, SLC2A9 | HTR1B 1596/4885HTR1D 945/4885HTR1F 686/4885 |
| US-20090143387-A1 | SUSTAINED-RELEASE TABLET COMPOSITION | SLC6A4, SLC6A2, CRH | HTR1B 35/4885HTR1D 33/4885HTR1F 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.